Autolus Therapeutics is shedding 20% of its workforce to cut costs, and is undertaking a management reshuffle as it looks to refocus after a rocky few years.
However, the UK biotech believes its lead CAR-T candidate, AUTO1, has the potential to be “transformational” in adult acute lymphoblastic leukaemia (ALL).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?